Neptune to Hold Conference Call to Discuss Second Quarter

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Neptune to Hold Conference Call to Discuss Second Quarter Results

LAVAL, Quebec, Oct. 8, 2014 (GLOBE NEWSWIRE) -- Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation") (Nasdaq: NEPT ) (TSX: NTB ), announced today that it will be holding a conference call on Wednesday October 15 at 9:00 AM (ET) to present its results for the second quarter ended August 31, 2014.

Conference Call Details:
Date: Wednesday October 15, 2014
Time: 9:00 AM Eastern Time
Conference ID: 14760800
Call: 1‐877-380-5664 (within Canada & the U.S.)
  1-631-813-4882 (Outside Canada and the U.S.)
  (Please dial in 15 minutes before the call begins)
   
Webcast: A live audio webcast can be accessed at:
  http://neptunekrilloil.com/investors/investor...entations/

An archived recording of the conference call will also be available on Neptune's website shortly after the call.

Neptune's audited consolidated financial statements for the second quarter ended August 31, 2014 and related MD&A will be available on SEDAR at sedar.com , on EDGAR at sec.gov/edgar.shtml and on the investor section of Neptune's website at neptunebiotech.com .

About Neptune Technologies & Bioressources Inc.

Neptune is a biotechnology company engaged primarily in the development and commercialization of marine-derived omega-3 polyunsaturated fatty acids ('' PUFAs ''). Neptune has a patented process of extracting oils from Antarctic krill, and principally sells omega-3 PUFAs as bulk oil to Neptune's distributors who commercialize them under their private label primarily in the U.S., European and Australian nutraceutical markets. Neptune's products generally come in bulk oil or capsule form and serve as a dietary supplement to consumers. Neptune's head office is located at 545 Promenade du Centropolis, Suite 100, Laval, Quebec.

Neptune holds approximately 49% of the participating and voting rights of Acasti Pharma Inc. (" Acasti ") and 95% of the voting rights of NeuroBioPharm Inc. (" NeuroBio "). Through these subsidiaries, Neptune is also pursuing opportunities in the medical food and prescription drug markets. Acasti and NeuroBioPharm respectively focus on the research and development of safe and therapeutically effective compounds for highly prevalent atherosclerotic conditions, such as cardiometabolic disorders and cardiovascular diseases, and for neurodegenerative and inflammation related conditions. Acasti's lead prescription drug candidate is CaPre ® , a purified high omega-3 phospholipid concentrate derived from Neptune krill oil being developed to address the prevention and treatment of cardiometabolic disorders, including hypertriglyceridemia, which is characterized by abnormally high levels of triglycerides.

Forward Looking Statements

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. securities laws and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of Neptune to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties,   readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.

The forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement and the "Cautionary Note Regarding Forward-Looking Information" section contained in Neptune's latest Annual Information Form, which also forms part of Neptune's latest annual report on Form 40-F, and which is available on SEDAR at www.sedar.com , on EDGAR at www.sec.gov/edgar.shtml and on the investor section of Neptune's website at www.neptunebiotech.com (the "AIF"). All forward-looking statements in this press release are made as of the date of this press release. Neptune does not undertake to update any such forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in Neptune public securities filings with the Securities and Exchange Commission and the Canadian securities commissions. Additional information about these assumptions and risks and uncertainties is contained in the AIF under "Risk Factors".

Neither NASDAQ nor the Toronto Stock Exchange accepts responsibility for the adequacy or accuracy of this release.

Neptune Contacts: Andre Godin Interim CEO and CFO +1.450.687.2262 neptunebiotech.com John Ripplinger Investor Relations +1.450.687.2262 neptunebiotech.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Philadelphia Firm Targets 100 Toys for Children This Holiday

Updated Category News Views 54

A hundred unopened toys can look modest on paper, yet that is exactly why this Philadelphia effort lands differently than the usual chest-thumping corporate charity chatter. van der Veen, Hartshorn & Levin has set a clear holiday target: collect 100 new, unwrapped toys for children in the Philadelphia area through the U.S. Marine Corps Reserve Toys for Tots program. No...

Continue Reading
Portillo's Faces Legal Heat: Investor Class Action Filed

Updated Category News Views 250

What’s Eating Portillo's? Ah, once upon a misstep in the land of promising expansion, now we have Portillo's Inc. (NASDAQ: PTLO) neck-deep in legal hot water. Those golden fries and famous sandwiches somehow didn't pave the way for stockholder bliss. Why the turmoil? On an ordinary November morning, the DJS Law Group made it clear: They're rallying the troops for a...

Continue Reading
AR Cards in Casino Gaming: A High-Stakes Revolution

Updated Category News Views 106

A New Breed of Casino Experience Walk into a casino today, and you might just enter a whole new reality. No, this isn’t a cheesy magician’s trick or a glitzy PR stunt—this is the real deal brought to you by augmented reality (AR) trading cards. Imagine the slots you love wrapped in a sci-fi movie where characters leap out, tap you on the shoulder, and call you by...

Continue Reading
LA Auto Show 2026: Thrills, Games, and Cars Galore

Updated Category News Views 82

A Family Day Like No Other at the LA Auto Show Kicking into gear this November, the 2026 Los Angeles Auto Show puts the pedal to the metal for families seeking a full day of fun without breaking the bank. We're talking about 10 solid days where auto-mania meshes with interactive experiences, all nestled in the Los Angeles Convention Center. Whether you're a gearhead or a...

Continue Reading
Texxon Faces Revenue Slide Amid Strategic Shifts

Updated Category News Views 176

Texxon's Strategic Transitions and Financial Headaches Texxon Holding Limited (NASDAQ:NPT) just laid their cards on the table, unveiling a mixed bag in their fiscal year 2026 results. As the world's chemical and plastics scene faces winds of change, Texxon buckled down and tried to steer the ship clear from the rocks. It's a balancing act juggling market headwinds, a new...

Continue Reading
PEGATRON Unveils AI and HPC Advances at SC26

Updated Category News Views 106

Revamping AI with High-Density Computing You know, back in the day, AI was just about training models and running basic inference. But now, it's all about these crazy agentic AI tasks—autonomous agents doing things I couldn't have imagined. PEGATRON's Evolution in Infrastructure PEGATRON's latest move at SC26 is a real leap forward in this ongoing AI saga. They're...

Continue Reading
Shareholder Alert: Investigation Looms Over GDYN

Updated Category News Views 103

Grid Dynamics Under Legal Scrutiny There’s nothing quite like waking up to find your pick embroiled in an investigation. Grid Dynamics Holdings, Inc. (NASDAQ: GDYN) is on the radar, with law firm Levi & Korsinsky diving headfirst into potential infractions of fiduciary duties by some of the company’s top brass. The Lowdown on the Investigation This whole circus was...

Continue Reading
Triple Crossing Tests a Tough Inland Marine Market

Updated Category News Views 0

Inland marine is where tidy insurance appetites go to get bent out of shape. A contractor’s rented machine, cargo moving between points, a half-finished building, or equipment that is neither parked forever nor easy to classify can turn a standard quote into a week of broker phone calls. Triple Crossing Specialty is stepping directly into that mess, launching a new...

Continue Reading
Operation Healing Forces Partners with Wounded Warrior

Updated Category News Views 80

Joining Forces for Special Operations Families When it comes to the heavy lifting of supporting Special Operations Forces (SOF) families, two powerhouses—Operation Healing Forces (OHF) and Wounded Warrior Project (WWP)—are doubling down. They’re not just tossing around good intentions. Oh no, they’re pulling out the stops with a solid partnership focused on...

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 359

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading

Top 5 Most Recently Viewed Articles

Revolutionary Gene Therapy Brings Hope to Young Patients

Updated Category News Views 279

Transformative Journey of Gene Therapy for AADC Deficiency Laughter and joy filled the sunny lobby of a research clinic, where a spirited little boy named Sriansh Ojha played happily with his sister, marking a dramatic contrast to his early life struggles. This remarkable transformation is largely due to gene therapy, a groundbreaking treatment that has changed the...

Continue Reading
Damon Inc. Unveils $30 Million Equity Offering for Mobility Innovation

Updated Category News Views 224

Introduction to Damon's Innovative Strategy Damon Inc. has recently announced a substantial $30 million Regulation A+ equity offering, which is set to enhance its impressive lineup of personal mobility products. The company, renowned for its electric motorcycles, aims to leverage the proceeds not only to fuel innovation in its products but also to fortify its...

Continue Reading
Cindy Eckert: Shaping the Future of Women's Health Together

Updated Category News Views 375

Cindy Eckert's Impact on Women's Health Innovation Cindy Eckert, the remarkable Founder and CEO of Sprout Pharmaceuticals, has been announced as the keynote speaker for the highly anticipated Women's Health Summit at Harvard Business School. This significant event, scheduled for 2025, aims to unite leaders, investors, and innovators dedicated to transforming women's...

Continue Reading
VoiceBrain and Diga-Talk Forge Partnership to Enhance Communications

Updated Category News Views 270

VoiceBrain and Diga-Talk Solutions Collaborate for Innovation In a groundbreaking partnership, VoiceBrain, renowned for its AI voice analytics, has teamed up with Diga-Talk Solutions, specialists in Push-to-Talk (PTT) over cellular technology. This exciting collaboration was unveiled during a prominent industry event, aiming to revolutionize real-time communication across...

Continue Reading
AstaReal's Research Reveals Astaxanthin Benefits for Kids' Eyes

Updated Category News Views 234

AstaReal's Groundbreaking Research on Astaxanthin AstaReal, Inc. has made a significant advancement in understanding children's eye health with its innovative research on astaxanthin. This powerful antioxidant, derived from the microalgae Haematococcus pluvialis, has been recognized globally for its benefits in enhancing visual performance, particularly in adults....

Continue Reading